Previvor Edge's AI Platform Delivers Cancer Risk Plans in a Single Visit

NEW YORK, NY – March 24, 2026 – Preventive cancer care organization Previvor Edge announced today a major expansion of its clinical platform, designed to dramatically accelerate the delivery of personalized cancer prevention strategies. The company is leveraging a proprietary artificial intelligence engine to provide patients with a comprehensive Cancer Risk Profile and an interactive digital care plan immediately following their first appointment, a process that previously required multiple visits and resulted in a static written report.

This development marks a significant shift in the field of preventive oncology, aiming to transform a historically fragmented and slow process into a streamlined, single-visit experience. By integrating complex genetic, medical, family history, and lifestyle data in real-time, the platform empowers clinicians to provide immediate, actionable guidance to patients seeking to understand and manage their cancer risk.

From Fragmented Data to Actionable Insight

For decades, the path to understanding one's cancer risk has been disjointed. Information from genetic tests, family health histories, personal medical records, and lifestyle choices often exists in separate, unconnected silos. Patients and their primary care physicians have been left with the daunting task of piecing together this complex puzzle, often without the specialized expertise required for comprehensive risk assessment.

This fragmentation creates what many in the field describe as an "education and implementation problem." The knowledge about risk factors may exist, but translating it into a cohesive and practical prevention plan has been a persistent challenge. This can lead to missed opportunities for early detection, underutilized preventive measures, and significant patient anxiety stemming from uncertainty.

Previvor Edge's expanded platform was built to address this core issue. By creating a system that synthesizes disparate data points, it aims to eliminate the information gaps and delays that have long plagued preventive care. The goal is to move beyond simply identifying risk to providing a clear, evidence-based roadmap for managing it.

A New Clinical Model Powered by AI

The company's new model hinges on its proprietary AI-powered data engine. This system is fed by a growing dataset informed by established clinical guidelines, published research, and insights from the company’s multidisciplinary clinical team and advisory board. The process begins before the patient even enters the clinic, with a brief online assessment of their history and lifestyle.

During a single clinical visit, a Previvor Edge clinician—part of a team that includes physicians, nurse practitioners, and genetic counselors—reviews this information alongside other relevant risk factors. The AI platform serves as a powerful decision-support tool, enabling the clinician to rapidly generate several key outputs:

• A structured Cancer Risk Profile that identifies elevated risks across numerous cancer types.
• A personalized prevention and early detection action plan based on the patient's unique profile.
• An interactive digital care plan with built-in educational resources and clear next steps.
• A shareable report for the patient's broader care team to ensure continuity of care.

Crucially, this is not a standalone automated report. The technology serves to augment, not replace, clinical expertise. The care plan and any adjustments are delivered as part of a collaborative discussion during the visit, ensuring recommendations are grounded in expert clinical judgment and tailored to the individual.

"This expansion allows us to deliver deeper insights to patients while maintaining the clinical expertise that is essential in cancer prevention," said Michelle Zimmerman, Co-Founder and CEO of Previvor Edge. "We're evaluating risk across many cancer types and translating that information into a clear, personalized plan that patients and their broader care team can act on."

Redefining the Standard for Preventive Oncology

By combining a multidisciplinary clinical team with its powerful AI engine, Previvor Edge is positioning itself as a new standard in a competitive landscape. While genetic testing companies have become adept at identifying hereditary risk, they often leave patients and their doctors to figure out the next steps. Similarly, specialized programs at academic medical centers, while excellent, are often limited in scale and accessibility.

Previvor Edge's model seeks to bridge these gaps. The platform is designed to scale the expertise of its team, which spans internal medicine, genetics, oncology, and lifestyle medicine. It provides a consistent, guideline-driven foundation that clinicians can use to personalize care, integrating advanced technologies like liquid biopsies, new algorithms, and imaging where appropriate for higher-risk individuals.

The company’s leadership brings significant credibility to this mission. Zimmerman previously built and led the oncology business at genomics leader Sema4 (now GeneDx), while co-founder Sven Karlsson is an experienced healthcare operator with a background in biotech and venture capital. This blend of clinical genomics and business-scaling experience has attracted early investor confidence, evidenced by a $3.3 million pre-seed funding round led by CoFound Partners and Max Ventures.

Patient Empowerment and the Path Forward

The ultimate goal of this technological and clinical integration is patient empowerment. By replacing ambiguity and fear with a clear, actionable 12-month plan, Previvor Edge aims to give patients a sense of control over their health. Early results from its clinical program are promising, indicating that over 90% of patients received a modified prevention or detection strategy that might have otherwise been overlooked.

Making such advanced, personalized care accessible is a key challenge. In a significant move to address this, Previvor Edge has launched its clinical program as an in-network provider with major insurers, including Aetna, United, and Cigna, reducing a major financial barrier for many patients.

As AI becomes more integrated into healthcare, the regulatory and ethical landscape continues to evolve. The emphasis from bodies like the FDA is on rigorous clinical validation and ensuring that AI tools support, rather than supplant, human decision-making. Previvor Edge's model, with its emphasis on a "human-in-the-loop" system and oversight from a high-profile clinical advisory board, appears designed to navigate this new terrain responsibly. By using AI as a sophisticated tool to augment clinical expertise, this approach may represent a scalable and clinically responsible path for the future of cancer prevention.